169 related articles for article (PubMed ID: 38227801)
1. Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis.
Dunn TN; Cope DI; Tang S; Sirupangi T; Parks SE; Liao Z; Yuan F; Creighton CJ; Masand RP; Alpuing Radilla L; Guan X; Detti L; Monsivais D; Matzuk MM
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38227801
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
[TBL] [Abstract][Full Text] [Related]
3. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
[TBL] [Abstract][Full Text] [Related]
4. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
5. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract][Full Text] [Related]
6. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Smeester BA; Slipek NJ; Pomeroy EJ; Laoharawee K; Osum SH; Larsson AT; Williams KB; Stratton N; Yamamoto K; Peterson JJ; Rathe SK; Mills LJ; Hudson WA; Crosby MR; Wang M; Rahrmann EP; Moriarity BS; Largaespada DA
Bone; 2020 Jul; 136():115353. PubMed ID: 32251854
[TBL] [Abstract][Full Text] [Related]
7. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
8. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of pexidartinib for microglia depletion and renewal.
Weyer MP; Strehle J; Schäfer MKE; Tegeder I
Pharmacol Ther; 2024 Jan; 253():108565. PubMed ID: 38052308
[TBL] [Abstract][Full Text] [Related]
11. Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.
Abeykoon JP; Lasho TL; Dasari S; Rech KL; Ranatunga WK; Manske MK; Tischer A; Ravindran A; Young JR; Tobin WO; Flanagan EP; Nowakowski KE; Ruan GJ; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Patnaik MM; Wu X; Witzig TE; Goyal G; Go RS;
Am J Hematol; 2022 Mar; 97(3):293-302. PubMed ID: 34978715
[TBL] [Abstract][Full Text] [Related]
12. Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes.
Boyd MM; Litscher SJ; Seitz LL; Messing A; Hagemann TL; Collier LS
J Neuroinflammation; 2021 Mar; 18(1):67. PubMed ID: 33685480
[TBL] [Abstract][Full Text] [Related]
13. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
[TBL] [Abstract][Full Text] [Related]
14. Pexidartinib: First Approval.
Lamb YN
Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
[TBL] [Abstract][Full Text] [Related]
15. The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro.
Mc Cormack B; Maenhoudt N; Fincke V; Stejskalova A; Greve B; Kiesel L; Meresman GF; Vankelecom H; Götte M; Barañao RI
Hum Reprod; 2021 May; 36(6):1501-1519. PubMed ID: 33748857
[TBL] [Abstract][Full Text] [Related]
16. Leptin receptor is induced in endometriosis and leptin stimulates the growth of endometriotic epithelial cells through the JAK2/STAT3 and ERK pathways.
Oh HK; Choi YS; Yang YI; Kim JH; Leung PC; Choi JH
Mol Hum Reprod; 2013 Mar; 19(3):160-8. PubMed ID: 23184927
[TBL] [Abstract][Full Text] [Related]
17. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells.
Okojie AK; Uweru JO; Coburn MA; Li S; Cao-Dao VD; Eyo UB
J Neuroinflammation; 2023 Oct; 20(1):242. PubMed ID: 37865779
[TBL] [Abstract][Full Text] [Related]
19. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
20. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
